INTRODUCTION {#SEC1}
============

*BCL-X* is a key apoptotic member of the *BCL-2* gene family that modulates tumor cell death and growth ([@B1]). Alternative splicing of exon 2 in the *BCL-X* pre-mRNA produces two isoforms, *BCL-XL* and *BCL-XS*, which have been shown to exert antagonistic functions in the apoptotic pathway ([@B4]), however, the mechanism that regulates the splice shifting between these two isoforms is incompletely understood. *BCL-XL*, the anti-apoptotic isoform, is highly expressed in a number of tumors ([@B5]) and elevated levels of *BCL-XL* have frequently been associated with aggressive disease and/or chemoresistance ([@B2]). In contrast, *BCL-XS* pro-apoptotic isoform abundance is low in tumor cells, and *BCL-XS* overexpression can sensitize these cells to chemotherapeutic agents ([@B6]), and can induce apoptosis in melanoma cells ([@B10],[@B11]).

The alternative splicing of *BCL-X* pre-mRNA has been shown to involve proteins, such as splicing-modulators or components of the exon junction complex ([@B12]), heterogeneous nuclear ribonucleoproteins ([@B18],[@B19]) and *BCL-X* pre-mRNA *cis*-element motifs ([@B20],[@B21]). Long non-coding RNAs (lncRNAs) are crucial players in cancer ([@B22]) and, although they have been recognized as regulators of gene expression, mainly by recruiting DNA-binding modulatory proteins that act on different genes and pathways ([@B26],[@B27]), the possible regulation of *BCL-X* splicing by lncRNAs has not been investigated.

A number of potentially oncogenic or anti-apoptotic lncRNAs, such as *PCGEM1* and *PANDA*, have been identified ([@B24],[@B25]), yet none of them act on the anti-apoptotic *BCL-2* gene family. Similarly, although four lncRNAs with tumor-suppressive or pro-apoptotic activities have been well characterized, namely, *lincRNA-p21*, *GAS5*, ncRNA *CCND1* and *MEG3* ([@B28]), none of them directly act on the *BCL-2* apoptotic pathway. Regarding gene splicing modulation, it has been long known to involve the small nuclear RNAs (snRNAs) ([@B32]), which along with the SR proteins and hnRNPs are components of the spliceosome. While a computational analysis has revealed an extensive relationship between long antisense RNAs and alternative splicing in the human genome ([@B33]), only a very limited number of lncRNAs has been shown to directly modulate alternative mRNA splicing. Thus, an endogenous transcript antisense to *N-myc* was shown to form an RNA-RNA duplex with the sense mRNA and to cause retention of *N-myc* intron 1 ([@B34]), however, the functional significance of this alternative splicing was not assessed ([@B34]). Related to apoptosis, splicing of the *Fas* protein-coding gene is influenced by the antisense *Saf* transcript ([@B35]), making the cells highly resistant to *Fas*-mediated apoptosis, which characterizes *Saf* as an anti-apoptotic lncRNA ([@B35]) with oncogenic activity. In a similar manner, a natural antisense transcript regulates the splicing of *Zeb2*, and is related to an increase in the production of oncogenic Zeb2 protein in human tumors ([@B36]). *MALAT1* is the only example of an oncogenic lncRNA ([@B37],[@B38]) that indirectly acts on alternative splicing through the modulation of the SR protein phosphorylation ([@B39]).

Here, we show a novel endogenous lncRNA that favors the accumulation of the pro-apoptotic *BCL-XS* isoform, thus having a tumor suppressor activity. This lncRNA is transcribed from the *BCL-X* genomic *locus* in the antisense direction relative to *BCL-X* mRNA, and we named it *INXS* for [in]{.ul}tronic *BCL-[XS]{.ul}*-inducing lncRNA. Our results support a view of *INXS* as a critical mediator of apoptosis that integrates damaging environmental conditions with the cellular events that lead to cell death.

MATERIALS AND METHODS {#SEC2}
=====================

Detailed experimental procedures are available as Supplementary Data.

RNA extraction and strand-specific reverse transcription-polymerase chain reaction (RT--PCR) {#SEC2-1}
--------------------------------------------------------------------------------------------

Total RNA was isolated from cultured cells with Trizol (Invitrogen) and purified with an RNAspin Mini kit (GE Healthcare) according to the manufacturer\'s instructions, with an extended treatment with DNase I for 1 h. Total RNA of excised xenograft tumors was extracted from paraffin-embedded tumor samples with the miRNeasy kit for formaline-fixed, paraffin-embedded (FFPE) tissues (217504, Qiagen) according to the manufacturer\'s instructions. Total RNA was quantified on ND-1000 (NanoDrop) and its integrity was assessed on a Bioanalyzer (Agilent). For measuring *INXS* in the strand-specific assays (Figure [1B](#F1){ref-type="fig"} and [C](#F1){ref-type="fig"}), reverse transcription (RT) was performed with SuperScript III (Invitrogen) using 3 μg of total RNA and a gene-specific primer listed in the Supporting Information. Controls for RT without primer (-primer) or without reverse transcriptase (-RT) in the reverse transcription step, followed by PCR (40 cycles, Figure [1B](#F1){ref-type="fig"}) or qPCR (Figure [1C](#F1){ref-type="fig"}) with the pair of *INXS* primers, were performed to confirm the absence of RNA self-priming and of genomic DNA contamination in the RT, respectively ([@B40]), thus ensuring the strand orientation specificity of the assay.

![Identification and characterization of *INXS* as an intronic antisense lncRNA downregulated in tumor cell lines. (A) Structure of the *BCL-X* gene locus on chromosome 20 with the *BLC-X* protein-coding mRNA being transcribed from the minus genomic strand and the antisense unspliced *INXS* lncRNA transcribed from the intronic region on the opposite strand. Gray boxes in *INXS* indicate transcript portions extended by RACE-PCR and sequencing. Small blue arrows next to *INXS* indicate PCR primers positions. (B) Antisense transcription \[AS\] of *INXS* lncRNA was detected by strand-specific RT-PCR in 786-O, DU145 and HepG2 cell lines. Sense transcription \[S\] was not detected in this *locus* region. C1 and C2 are negative controls. (C) *INXS* expression levels across a panel of tumor (light blue) and non-tumor (dark blue) cell lines from kidney, liver, breast and prostate. Absolute quantification of *INXS* was obtained for each cell line and the relative abundance is shown with respect to the absolute amount measured in the CaKi-1 cell line (175 molecules per ng of total RNA). (D) *BCL-XS* (black) and *BCL-XL* (red) mRNA isoform levels across a panel of tumor (T) and non-tumor (NT) cell lines from kidney, liver, breast and prostate. Expression levels are relative to the expression of the *BCL-XS* isoform in the CaKi-1 cell line. The data are the mean ± SD of three independent experiments. \*(*P* \<0.05), \*\*(*P*\<0.01) and \*\*\*(*P* \<0.001).](gku561fig1){#F1}

RT-qPCR {#SEC2-2}
-------

For measuring *INXS* lncRNA and protein-coding mRNAs, reverse transcription was performed with the SuperScript III (Invitrogen) using 1 μg of total RNA and oligo-dT primer, followed by qPCR as described in the Supplementary Data.

RACE-PCR {#SEC2-3}
--------

For RACE-PCR we used the Human Fetal Kidney Marathon-Ready cDNA (Clontech, No. 639323) commercial library prepared from poly(A) RNA extracted from a pool of 59 spontaneously aborted fetal kidneys. Gene-specific primers are listed in the Supplementary Data.

Transient plasmid or oligonucleotide transfections {#SEC2-4}
--------------------------------------------------

Cells were transfected with pCEP4-INXS plasmid using FuGENE HD (Promega) for the *INXS* overexpression assays. For *INXS* knockdown assays, cells were transfected with modified antisense oligonucleotides (ASOs) using lipofectamine RNAimax (Invitrogen). See details of ASOs titrations under Supplementary Data.

Apoptosis assay and fluorimetric determination of caspase activity {#SEC2-5}
------------------------------------------------------------------

Cell viability was determined by staining with Annexin V FITC and propidium iodide (Invitrogen) by flow cytometry (Beckman Coulter FC500 MPL). Caspase activities were measured with specific fluorigenic substrates and the respective caspase inhibitors (Kamiya Biomedical); see details under Supplementary Data.

Nude mouse xenograft assays {#SEC2-6}
---------------------------

Generation of human kidney tumor 786-O cell mouse xenografts and intra-tumor injections of pCEP4-empty or pCEP4-INXS plasmids dissolved in TurboFect *in vivo* transfection solution (Fermentas) are described in detail under Supplementary Data.

RESULTS {#SEC3}
=======

*INXS* is a long non-coding antisense transcript {#SEC3-1}
------------------------------------------------

To identify lncRNAs with a possible involvement in the regulation of cell apoptosis, we searched the public databases for ESTs and mRNAs that mapped to gene *loci* encoding proteins from the *BCL-2* family. A detailed analysis of the *BCL-X* genomic *locus* on human chromosome 20 revealed at least 70 unspliced ESTs covering 1291 bp in that *locus* (Figure [1A](#F1){ref-type="fig"}, thin black box on upper strand), which overlapped the 5′-UTR portion of *BCL-X*. We performed 5′- and 3′-RACE assays using a human fetal kidney cDNA library, sequenced the products and detected an unspliced 1903 nt-long transcript, which extended the ESTs evidence by 537 nt and 75 nt at the 5′- and 3′-ends, respectively (Figure [1A](#F1){ref-type="fig"}, thin gray boxes on the upper strand). The full-length transcript spanned beyond exons 1 and 2, overlapping intron 1 and some of the genomic regions upstream of *BCL-X* (Figure [1A](#F1){ref-type="fig"}). The antisense directionality of this transcript relative to mRNAs encoded in the *BCL-X locus* was determined by strand-oriented RT-PCR in three human cell lines (Figure [1B](#F1){ref-type="fig"}), namely, 786-O kidney tumor, DU145 prostate tumor and HepG2 liver tumor cell lines, and the identity of the PCR product was confirmed by sequencing. It is worth noting that no transcript was observed in the sense controls (Figure [1B](#F1){ref-type="fig"}), indicating that no DNA contaminant was present, and also indicating that the levels of *BCL-X* pre-mRNA that accumulate in these cell lines are undetectable. An *in silico* analysis with the CPC Coding Potential Calculator tool ([@B41]) showed no coding potential for the transcript, and we named it *INXS*, for [in]{.ul}tronic *BCL-[XS]{.ul}*-inducing lncRNA.

*INXS* is less abundant in a set of different tumor cell lines and in kidney tumor tissues compared with non-tumors {#SEC3-2}
-------------------------------------------------------------------------------------------------------------------

Tumor cell lines from kidney, liver, breast and prostate showed an endogenous *INXS* expression that was 5- to 9-fold lower compared with non-tumor cell lines derived from the same tissues (Figure [1C](#F1){ref-type="fig"}). In parallel, we measured the relative abundance of *BCL-X* protein-coding mRNA in all studied cell lines, and found that the *BCL-X* expression had the opposite pattern, being higher in the tumor than in the non-tumor cell lines studied (Figure [1D](#F1){ref-type="fig"}). More importantly, the *BCL-XS* pro-apoptotic isoform was relatively lower in tumor than in non-tumor cell lines derived from all four different tissues that we have studied (Figure [1D](#F1){ref-type="fig"}, black bars).

Because the *INXS* tumor/non-tumor abundance ratio in kidney cell lines was the lowest among the cell lines of different origins that were tested, we chose the kidney tumor cell line 786-O as a model for the characterization of the induction of endogenous *INXS* expression, as described further below. In this cell line the absolute level of *INXS* corresponds to ∼5 copies per cell, whereas *BCL-XS* is 2-fold higher (12 copies per cell), and *BCL-XL* is 35-fold higher than *INXS* (167 copies per cell).

Next, we analyzed *INXS* endogenous expression in the post-nephrectomy kidney samples of 13 patients with renal cell carcinoma, and observed quite variable levels of *INXS* (Supplementary Figure S1A). Interestingly, in all patient samples, when the *INXS* level of the non-tumor tissue was set to 1, we found that the *INXS* levels were 2- to 60-fold lower in the tumor tissue compared with the matched non-tumor (Supplementary Figure S1B). Again, *BCL-X* protein-coding mRNA relative abundance had the opposite pattern, being significantly higher in the tumor than in the paired non-tumor (Supplementary Figure S1C), and *BCL-XS* pro-apoptotic isoform was similarly lower in tumor tissues compared with matched non-tumor tissues (Supplementary Figure S1C, black bars) in all 13 kidney cancer patient samples.

Thus, there is a concomitant lower expression of *INXS* lncRNA and of *BCL-XS* pro-apoptotic mRNA isoform both in the tumor cell lines that have been studied and in the kidney patient tumor samples that have been analyzed compared with non-tumor, suggesting that *INXS* might play a role in *BCL-X* splicing regulation.

### *INXS* knockdown in a non-tumor cell line causes a significant reduction in the *BCL-XS*/*BCL-XL* ratio {#SEC3-2-1}

To test if *INXS* is a regulator of *BCL-X* expression, we did knockdown *INXS* in the RC-124 non-tumor kidney cell line, which has relatively higher levels of endogenous *INXS* compared with kidney tumor cell lines (see Figure [1C](#F1){ref-type="fig"}), and we monitored the effect on *BCL-X* isoform levels. A reduction of 60% in the endogenous level of *INXS* (*P* \< 0.05) (Figure [2A](#F2){ref-type="fig"}) caused a significant reduction in the *BCL-XS* isoform (*P* \< 0.05) (Figure [2B](#F2){ref-type="fig"}) and the *BCL-XS/BCL-XL* ratio was significantly reduced from 0.25 to 0.15 (*P* \< 0.01) (Figure [2C](#F2){ref-type="fig"}), showing that *INXS* regulates the levels of *BCL-X* isoforms.

![*INXS* knockdown in the non-tumor kidney cell line RC-124 reduces the *BCL-XS*/*BCL-XL* ratio. (A) *INXS* knockdown in the RC-124 cell line using two distinct INXS-knockdown ASOs (INXS-ASO-1 and -2) reduces by 60% the endogenous levels of *INXS* compared to a control scrambled oligonucleotide transfection. (B) The levels of *BCL-XS* (black) and *BCL-XL* (red) mRNA isoforms in the same cells were measured by RT-qPCR. (C) *BCL-XS*/*BCL-XL* mRNA ratio in these cells was significantly reduced from 0.25 to 0.15 upon transfection with INXS-ASO-1 and -2. The data are the mean ± SD of three independent experiments. \*(*P* \<0.05), and \*\*(*P*\<0.01).](gku561fig2){#F2}

Long non-coding RNA *INXS* is an RNAPII-encoded, 5′-capped, stable and nuclear-enriched transcript {#SEC3-3}
--------------------------------------------------------------------------------------------------

Inspection of the ChIP-seq data from the ENCODE project ([@B42]) indicated that the RNA polymerase II (RNAPII) chromatin mark was enriched at the putative transcription start site of *INXS* within the *BCL-X* genomic locus. To determine if *INXS* is transcribed by RNAPII, cells were treated with the RNAPII inhibitor α-amanitin; ∼90% reduction of *INXS* levels was observed (Figure [3A](#F3){ref-type="fig"}). In addition, we determined that the *INXS* lncRNA is modified by a methyl-guanosine cap, using the tobacco acid pyrophosphatase/5′exonuclease assay (Figure [3B](#F3){ref-type="fig"}). The half-life of *INXS* was determined to be ∼3 h (Figure [3C](#F3){ref-type="fig"}). For comparison, the measured half-life of *MYC* was 29 min, which is comparable with its half-life in the literature ([@B43]). Cell fractionation experiments revealed that *INXS* is predominantly enriched in the nucleus (Figure [3D](#F3){ref-type="fig"}).

![Characterization of *INXS* biogenesis, stability and cellular localization. (A) RNAPII inhibition with α-amanitin decreases the levels of *INXS*. Known RNAPII-transcribed (*ACTB*, *MYC*) and RNAPIII-transcribed genes (pre-tRNA^Tyr^, 7SK) were assayed as controls. (B) The presence of a 5′-end cap modification in *INXS* was determined by digestion with terminator 5′-phosphate-dependent exonuclease (5′Exo) in combination with tobacco acid pyrophosphatase (TAP), as indicated. *TUBA1C* tubulin gene was assayed as a control. (C) *INXS* decay rate in cells treated with actinomycin D, a transcription inhibitor. *MYC* was measured in parallel as a positive control of the decay assay. (D) Relative distribution of *INXS* in the nuclear and cytoplasmic fractions (N/C ratio). The nuclear-enriched *MALAT1* lincRNA and the 45S rRNA were used as nuclear fraction controls and the 18S rRNA as a cytoplasmic fraction control. As an additional control, western blot of the protein extracts from the fractions was performed, detecting GAPDH only in the cytoplasmic fraction, and histone H3 only in the nuclear fraction. Further controls for cell fractionation are described in the Supplementary Data. \*(*P* \<0.05), \*\*(*P* \<0.01) and \*\*\*(*P* \<0.001).](gku561fig3){#F3}

Endogenous *INXS* expression is driven by an independent promoter {#SEC3-4}
-----------------------------------------------------------------

A putative promoter region containing a GC box and TATA box was *in silico* predicted within a 670 bp genomic region just upstream of the *INXS* transcription start site (Supplementary Figure S2A), and here, we named it the antisense promoter. In a luciferase promoter assay, this 670-bp fragment (pGL3-antisense) showed an activity that was similar to that of the strong SV-40 promoter (pGL3-SV40), thus indicating that this promoter is able to drive transcription from the genomic plus strand (Supplementary Figure S2B). A short 250-bp DNA fragment from the same region that lacked the GC and TATA box (pGL3-short antisense) showed negligible promoter activity (Supplementary Figure S2B). In addition, the inverted genomic DNA sequence (pGL3-inverted) showed no activity (Supplementary Figure S2B), indicating that this is a directional promoter.

*INXS* endogenous expression is increased by apoptosis-inducing agents {#SEC3-5}
----------------------------------------------------------------------

To evaluate if the endogenous levels of *INXS* are modulated by damaging environmental conditions, we treated the 786-O kidney tumor cell line with three agents that lead to apoptosis. First, we found that the exposure of cells to 40 J/m^2^ UV-C light did trigger a time-dependent increase of *INXS*, leading to a 5-fold enhancement at 24 h after UV-C exposure (Figure [4A](#F4){ref-type="fig"}). When we looked at the individual *BCL-X* isoforms, we observed that the pro-apoptotic *BCL-XS* isoform increased 7-fold (Figure [4B](#F4){ref-type="fig"}, black), with a concomitant decrease in anti-apoptotic *BCL-XL* (Figure [4B](#F4){ref-type="fig"}, red). The net result was a 10-fold *BCL-XS/BCL-XL* ratio increase from 0.06 at time zero to 0.6 at 24 h after UV-C exposure (Figure [4C](#F4){ref-type="fig"}); interestingly there was no change in the abundance of total *BCL-X* mRNA (Supplementary Figure S3A).

![*INXS* endogenous expression is increased by apoptosis-inducing agents and is associated with increased *BCL-XS* mRNA and caspases activation. (A, E, I) Induced expression of *INXS* lncRNA in 786-O kidney tumor cells by exposure (A) to 40 J/m2 UV-C light for 40 s at time zero, (E) to serum reduction for 24 h or (I) to sulforaphane anti-cancer drug (SFN) for up to 24 h. (B, F, J) Levels of *BCL-XS* (black) and *BCL-XL* (red) mRNA isoforms in the same cells. (C, G, K) *BCL-XS*/*BCL-XL* mRNA ratio in the cells. (D, H, L) Activation of caspase 3 and caspase 9 in 786-O cells at 24 h after the exposure to (D) 40 J/m^2^ UV-C, (H) 0.5% serum or (L) SFN. (See Supplementary Figure S4 for other caspases.) \*(*P* \<0.05), \*\*(*P* \<0.01) and \*\*\*(*P* \<0.001).](gku561fig4){#F4}

Next we measured the activation of caspases as a proxy for the mitochondrially mediated apoptosis induced by the increase in the levels of *BCL-XS* mRNA. In fact, Plotz *et al.* ([@B10]) have shown that an increase in *BCL-XS* mRNA results in an increase in BCL-XS protein abundance, with an increase in the protein--protein interaction between BCL-XS and VDAC2 (voltage-dependent anion channel 2) and release of Bak from VDAC2. This in turn triggers apoptosis by activation of caspases 3 and 9 ([@B10]). We found that the increase in *BCL-XS* mRNA caused by UV-C exposure was followed by activation of the intrinsic apoptosis pathway, as determined by a 10-fold activation of both effector caspase 3 and initiator caspase 9 (Figure [4D](#F4){ref-type="fig"}) and a 3.5-fold activation of caspase 7 (Supplementary Figure S4A). Caspase 8 from the extrinsic apoptotic pathway was not activated by UV-C exposure (Supplementary Figure S4A).

A similar pattern of increased *INXS* expression was obtained 24 h after reducing the serum in the culture medium in a dose-dependent manner from 10% to 5%, 1% and 0.5% (Figure [4E](#F4){ref-type="fig"}), which resulted in similar *BCL-X* isoforms shift patterns, and in the activation of caspases (Figure [4F](#F4){ref-type="fig"}--H, Supplementary Figures S3B and S4B).

Treatment with the anti-cancer agent sulforaphane (SFN) induces cell-cycle arrest and apoptosis and causes a reduction in anti-apoptotic *BCL-XL* expression ([@B44]). After 24 h exposure of 786-O cells to SFN (50 μM), there was a 10-fold increase in *INXS* expression (Figure [4I](#F4){ref-type="fig"}), which was again accompanied by similar changes in *BCL-X* isoforms and in the activation of caspases (Figure [4J](#F4){ref-type="fig"}--L, Supplementary Figures S3C and S4C).

*INXS* is required for caspase activation caused by apoptosis-inducing agents {#SEC3-6}
-----------------------------------------------------------------------------

The transfection of 786-O cells with two different ASOs complementary to *INXS* lncRNA significantly abrogated the increase in *INXS* levels caused by the three apoptosis-inducing agents, namely, UV-C exposure (Figure [5A](#F5){ref-type="fig"}), serum reduction to 0.5% (Figure [5E](#F5){ref-type="fig"}) or SFN treatment (Figure [5I](#F5){ref-type="fig"}). Under *INXS* knockdown, the increase in the pro-apoptotic *BCL-XS* isoform was equally abrogated under these three cell treatments (Figure [5B](#F5){ref-type="fig"}, [F](#F5){ref-type="fig"} and [J](#F5){ref-type="fig"}, black bars), and the shift in the *BCL-XS/BCL-XL* ratio toward the pro-apoptotic *BCL-XS* isoform was significantly reduced in all three conditions (Figure [5C](#F5){ref-type="fig"}, [G](#F5){ref-type="fig"} and [K](#F5){ref-type="fig"}). As a consequence of *INXS* knockdown, the activation of both effector caspase 3 (Figure [5D](#F5){ref-type="fig"}, [H](#F5){ref-type="fig"} and [L](#F5){ref-type="fig"}, red bars) and initiator caspase 9 (Figure [5D](#F5){ref-type="fig"}, [H](#F5){ref-type="fig"} and [L](#F5){ref-type="fig"}, green bars) was significantly abrogated in all three conditions. Caspases 7 and 8 activities were less affected or not affected by *INXS* knockdown (Supplementary Figure S4D--F).

![*INXS* knockdown abrogates the effect of apoptosis-inducing agents. (A, E, I) Abrogated induction of *INXS* expression in the presence of two distinct INXS-knockdown ASOs (INXS-ASO-1 or -2), with cells exposed (A) to 40 J/m2 UV-C light for 40 s at time zero and incubated for 24 h, (E) to serum reduction (0.5 % serum) for 24 h or (I) to sulforaphane anti-cancer drug (SFN) for 24 h. (B, F, J) The increase in *BCL- XS* (black) and the decrease in *BCL-XL* (red) mRNA isoforms induced by the apoptotic agents are abrogated in the presence of two distinct INXS-knockdown ASOs (INXS-ASO-1 or -2). (C, G, K) The increase in *BCL-XS*/*BCL-XL* mRNA ratio is significantly abrogated in the INXS-knockdown treated cells. (D, H, L) Abrogated activation of caspase 3 and caspase 9 in the presence of two distinct INXS-knockdown ASOs (INXS-ASO-1 or -2). (See Supplementary Figure S4 for other caspases.) In all panels, the data are the mean ± SD of three independent experiments. \*(*P* \<0.05), \*\*(*P* \<0.01) and \*\*\*(*P* \<0.001).](gku561fig5){#F5}

We have titrated the effectiveness of the two ASOs in reducing *INXS* levels in the 786-O kidney tumor cell line after induction of *INXS* by UV-C exposure (Supplementary Figure S5). Using the two distinct ASOs in the range 50, 100 and 200 nM, each one separately and the two in combination, we found a dose-dependent reduction of *INXS* with increasing concentrations of the ASOs (Supplementary Figure S5A). In parallel, we observed a progressive change in the *BCL-X* isoforms, and a progressive reduction in the *BCL-XS/BCL-XL* ratio with increasing ASOs (Supplementary Figure S5B). Similar extents of reduction were obtained for each of the two ASOs separately, at 500 nM each (Figure [5A](#F5){ref-type="fig"}). In spite of having obtained the most pronounced *INXS* knockdown effect with the combination of ASO-1 plus ASO-2 (Supplementary Figure S5), we have favored the ability to test the two distinct ASOs separately (Figure [5](#F5){ref-type="fig"}), in order to be able to collect independent evidence of phenotypic effects elicited for each of the two distinct ASOs. This adds to the evidence of a specific effect related to *INXS* knockdown.

Taken together, the similar findings obtained for the three different apoptosis-inducing cell treatments and the two ASOs (Figure [5](#F5){ref-type="fig"} and Supplementary Figure S5) confirm *INXS* as a critical mediator of *BCL-XS* splice regulation and of cell death caused by apoptosis-inducing agents.

Overexpression of *INXS* increases *BCL-XS* isoform abundance and leads to apoptosis *in vitro* {#SEC3-7}
-----------------------------------------------------------------------------------------------

To test the effect of *INXS* ectopic overexpression on *BCL-X* alternative splicing, 786-O cells were transiently transfected with increasing concentrations of a pCEP4-INXS vector; after 24 h, the transfected 786-O cells showed a 15- to 40-fold increase in *INXS* compared with the endogenous *INXS* lncRNA expression level in untransfected cells (Figure [6A](#F6){ref-type="fig"}, blue bars). The mRNA abundance of the *BCL-XL* isoform was reduced up to 4-fold in 786-O cells transfected with 3 μg of plasmid compared with wild-type cells (Figure [6A](#F6){ref-type="fig"}, red bars). Interestingly, *BCL-XS* mRNA expression showed a 20-fold increase relative to that of wild-type (Figure [6A](#F6){ref-type="fig"}, black bars). It is noteworthy that the relative abundance ratio of *BCL-XS*/*BCL-XL* was markedly increased, up to ∼60-fold (Figure [6B](#F6){ref-type="fig"}), from 0.06 in untransfected cells to 3.3 in cells with the highest level of *INXS* lncRNA overexpression; no change in the total *BCL-X* mRNA (Figure [6C](#F6){ref-type="fig"}) was observed. At the highest *INXS* lncRNA levels, the pro-apoptotic *BCL-XS* isoform was clearly predominant (∼80% of all *BCL-X* mRNA in the cell).

![Overexpression of *INXS* induces BCL-XS mRNA and protein and promotes apoptosis. (A) The levels of *BCL-XS* (black) and *BCL-XL* (red) mRNA isoforms were measured by RT-qPCR in 786-O kidney tumor cells 24 h after transient transfection with increasing amounts of pCEP4-INXS plasmid (*INXS* lncRNA levels = blue bars). All expression levels are shown as relative abundance with respect to the endogenous *INXS* in wild-type cells. (See Supplementary Figure S6A and F for similar effects on the MCF7 and PC3 cell lines.) (B) The increase in *BCL-XS/BCL-XL* ratio is dependent on the extent of *INXS* overexpression. (C) Total *BCL-X* mRNA does not change upon *INXS* overexpression. (D) Augmented apoptosis upon transfection of 786-O cells with increasing amounts of pCEP-INXS plasmid, as detected by flow cytometry using double labeling with Annexin V FITC (AV FITC, *x*-axis) and propidium iodide (PI, *y*-axis). The percentage of cells that were labeled with AV FITC is shown in the quadrants marked with blue broken lines. (See Supplementary Figure S6D and I for similar effects on the MCF7 and PC3 cell lines.) (E) The results from (D) are shown as the fraction of labeled cells relative to the total. (F) Western blot detects the BCL-XS protein isoform upon *INXS* overexpression. Antibody anti-BCL-X was used for immunoprecipitation of 786-O cell lysates, and the IP fraction was analyzed by western blot with the same antibody. Three independent replicate transfection experiments are shown. (G) Densitometric intensity ratio between BCL-XS and BCL-XL signals from the data on panel F (the background intensity signal was used as a proxy for BCL-XS in the controls). (H) Caspases 3, 7 and 9 are activated upon *INXS* overexpression in 786-O cell line, while caspase 8 is not affected. (See Supplementary Figure S9 for detection of active caspase 3 by immunofluorescence microscopy.) In all panels except in D and F, the data are the mean ± SD of three independent experiments. \*\*(*P* \<0.01) and \*\*\*(*P* \<0.001).](gku561fig6){#F6}

The efficiency of *INXS* lncRNA ectopic overexpression in affecting *BCL-X* mRNA alternative splicing was tested in two additional tumor cell lines, namely, the breast tumor MCF7 cell line (Supplementary Figure S6A--C) and the prostate tumor PC3 cell line (Supplementary Figure S6F--H), showing similar patterns of dose-dependent *BCL-XS* mRNA increase upon ectopic overexpression of *INXS* lncRNA, with a concomitant *BCL-XL* decrease and a sustained level of total *BCL-X*.

Having determined that *INXS* overexpression alters the *BCL-X* splicing pattern in 786-O, MCF7 and PC3 cell lines, we next examined its effect on cell apoptosis. Cells overexpressing *INXS* lncRNA showed a dose-dependent increase in apoptosis; the population of apoptotic 786-O kidney cells labeled with Annexin V FITC increased from 15% in 786-O cells transfected with 1 μg of pCEP4-INXS plasmid (Figure [6D](#F6){ref-type="fig"}, left bottom panel) to ∼42% in cells transfected with 3 μg of plasmid (Figure [6D](#F6){ref-type="fig"}, right bottom panel). The apoptosis-inducing effect of *INXS* overexpression was very reproducible among three biological replicates (Figure [6E](#F6){ref-type="fig"}), and the average fraction of apoptotic cells (AV^+^PI^−^ plus AV^+^PI^+^) in the population significantly increased from ∼15% in 786-O cells transfected with 1 μg of plasmid to ∼40% in cells transfected with 3 μg of *INXS*-expressing plasmid (Figure [6E](#F6){ref-type="fig"}). Apoptosis induced by *INXS* lncRNA overexpression as detected by Annexin V-FITC labeling was reproduced in the two other tumor cell lines tested, namely, the MCF7 breast tumor (Supplementary Figure S6D and E) and PC3 prostate tumor (Supplementary Figure S6I and J).

The above-described phenotype was not observed when we overexpressed *ANRASSF1*, a similar but unrelated unspliced lncRNA that is endogenously transcribed antisense to the *RASSF1A* gene in prostate cancer cells ([@B45]). Upon overexpression of *ANRASSF1* in 786-O kidney tumor cells, no change in *BCL-XS* or *BCL-XL* isoform levels was detected (Supplementary Figure S7A and B). In addition, no apoptosis was observed in *ANRASSF1*-overexpressing cells using the Annexin V-PI assay (Supplementary Figure S7C), providing further support that the apoptotic phenotype was the result of a specific effect elicited by *INXS* lncRNA overexpression.

Overexpression of *INXS* increases BCL-XS protein and activates caspases 3, 7 and 9 {#SEC3-8}
-----------------------------------------------------------------------------------

The effect of *INXS* lncRNA overexpression on *BCL-X* mRNA isoforms was tested at the protein level. Because too many dying cells were accumulated 24 h after transfection with the *INXS*-expressing plasmid (3 μg plasmid), which reduced our ability to collect viable cells for the western blot assays, we first determined the shortest time of overexpression at which to perform the western blots. By measuring the time course of *INXS* lncRNA and *BCL-XS* mRNA increase following the transient transfection of 786-O cells (Supplementary Figure S8A and B), we found that as early as 15 h after transfection there was already a 22-fold increase in *INXS* lncRNA compared with the endogenous (Supplementary Figure S8A), and an 18-fold increase in *BCL-XS* pro-apoptotic mRNA isoform (Supplementary Figure S8B), with a concomitant 2.5-fold reduction in BCL-XL mRNA (Supplementary Figure S8C). At 15 h after transfection a significant 18-fold increase in the *BCL-XS*/*BCL-XL* ratio from 0.06 to 1.2 was obtained (Supplementary Figure S8D).

Thus, transfected cells collected at 15 h were lysed, BCL-X protein isoforms were immunoprecipitated with anti-BCL-X antibody and the IP fraction was analyzed by western blot. A distinct BCL-XS band was detected only in the *INXS*-overexpressing cells but not in the control (Figure [6F](#F6){ref-type="fig"}). The densitometric intensity ratio between BCL-XS and BCL-XL signals significantly increased from 0.2 in the control cells (where the background intensity signal was used as a proxy for BCL-XS abundance) to 2.8 in the *INXS*-overexpressing cells (Figure [6G](#F6){ref-type="fig"}). The amount of BCL-XL isoform apparently did not decrease after 15 h of *INXS* overexpression (Figure [6F](#F6){ref-type="fig"}), suggesting that the BCL-XL protein turnover is longer than the *BCL-XL* mRNA turnover (Supplementary Figure S8C). It is noteworthy that BCL-XS protein abundance in non-apoptotic human cell lines is relatively low, and was shown to be below western blot detection limits in melanoma ([@B10],[@B46]) or lung adenocarcinoma ([@B8]) cell lines. The difficulties in detection of the BCL-XS protein isoform was also observed here in 786-O kidney tumor cells, which led us to use the IP approach.

The overexpression of *INXS* lncRNA caused a significant activation of caspases 3, 7 and 9, the major caspases in the mitochondrially mediated apoptosis pathway, but had no effect on initiator caspase 8 of the death receptor extrinsic pathway (Figure [6H](#F6){ref-type="fig"}).

The apoptotic phenotype was further confirmed by immunofluorescence imaging with an anti-active caspase 3 antibody, which showed a stronger signal in the 786-O cell line transfected with pCEP4-INXS vector when compared with the control (Supplementary Figure S9). These results are entirely in agreement with the role of BCL-XS protein in activating the mitochondrially mediated apoptosis pathway ([@B10]).

*INXS* interacts with Sam68 splicing-modulator complex {#SEC3-9}
------------------------------------------------------

Because the Sam68 splicing-modulator complex regulates the alternative splicing of *BCL-X* pre-mRNA ([@B12]), we performed a native Ribonucleoprotein immunoprecipitation (RIP) assay with an anti-Sam68 antibody to determine if *INXS* lncRNA binds to Sam68-containing ribonucleoprotein (RNP) complexes. The immunoprecipitated proteins were digested, and the protein-bound RNAs were measured with RT-PCR. In this assay, the *INXS* lncRNA was detected as bound to Sam68-containing RNP complexes (Figure [7A](#F7){ref-type="fig"}). As positive controls, *BCL-XL* and *BCL-XS* mRNAs were also detected as bound to the Sam68-containing RNP complex (Figure [7A](#F7){ref-type="fig"}), in agreement with previous reports ([@B12]). The negative control *BCL-2* mRNA ([@B12]), which is known to not bind to Sam68, was not detected in the immunoprecipitate (Figure [7A](#F7){ref-type="fig"}). As expected, Sam68 was detected in the immunoprecipitate fraction of the anti-Sam68 RIP assay, by a western blot with the same anti-Sam68 antibody (Figure [7A](#F7){ref-type="fig"}).

![*INXS* interacts with the Sam68 splicing-modulator complex. (A) Native RIP (RNA-binding protein immunoprecipitation) assay with anti-Sam68 antibody was performed, followed by RT-PCR with primers for the indicated genes. A negative control, from RNA-IP with immunoglobulin G (IgG) was included. For *INXS* lncRNA, a strand-specific primer was used for RT. For the positive controls (*BCL-XL* and *BCL-XS* mRNAs) and the negative control (*BCL-2* mRNA), oligo-dT primer was used for RT. The protein fraction from the native RIP assay with anti-Sam68 antibody was analyzed by western blot, which was developed with the same antibody. A negative control sample, from RIP with IgG, was included. (B) *INXS* overexpression was performed in the 786-O kidney tumor cell line with 3 μg of *INXS*-expressing plasmid for 24 h and the alternative splicing isoforms of two Sam68 target mRNAs that have been identified in the literature, namely, *CCDN1-v1* and *SRSF1-v1* and *-v2*, were measured by RT-qPCR. (C) *INXS* knockdown was performed in the RC-124 kidney non-tumor cell line as in Figure [2](#F2){ref-type="fig"}, and the levels of *CCDN1-v1* and *SRSF1-v1* and *-v2* were measured by RT-qPCR. The data are the mean ± SD of three independent experiments.](gku561fig7){#F7}

Overexpression or knockdown of *INXS* does not affect the splicing of other Sam68 target mRNAs {#SEC3-10}
----------------------------------------------------------------------------------------------

We monitored the effects of *INXS* overexpression on splicing of two additional Sam68 target mRNAs that have been identified in the literature, namely, the proto-oncogenes *cyclin D1(CCDN1-v1)* ([@B47]) and *SF2/ASF* (*SRSF1-v1* and *-v2*) ([@B48]). As shown in Figure [7B](#F7){ref-type="fig"}, overexpression of *INXS* did not affect the splicing of either *cyclin D1(CCDN1-v1)* or *SF2/ASF (SRSF1-v1 and -v2)*. We also monitored the effect of *INXS* knockdown on these Sam68 mRNA targets and observed no effect on splicing of these genes (Figure [7C](#F7){ref-type="fig"}).

*INXS* induces tumor regression *in vivo* {#SEC3-11}
-----------------------------------------

To determine the potential of the *INXS* lncRNA to affect tumor growth *in vivo*, ectopic overexpression of *INXS* was tested in nude mice 786-O kidney tumor cells xenograft assays. Tumor cells were inoculated subcutaneously into 12 female athymic nude mice on day --63 (Figure [8A](#F8){ref-type="fig"}), and when the tumors reached approximately the same volume of 250 mm^3^ (day zero) the animals were randomly separated into two groups that were injected either with *INXS* or empty pCEP4 vectors. Intra-tumor injections of the plasmid-containing transfectant solution started at day zero and proceeded at every third day for 15 days (Figure [8A](#F8){ref-type="fig"}). The tumor volume for each animal was measured with the caliper at each injection day (Figure [8B](#F8){ref-type="fig"}). At day 15, in all animals injected with *INXS* lncRNA plasmid the average tumor volume was reduced to 70 mm^3^ (Figure [8B](#F8){ref-type="fig"}), an average 8-fold tumor regression as compared to the tumors of animals injected with empty vector (570 mm^3^) (Figure [8B](#F8){ref-type="fig"}).

![Overexpression of *INXS* induces tumor regression *in vivo*. (A) Schematic representation showing the subcutaneous inoculation of mice with 786-O human kidney tumor cells (open arrow, on day --63), followed by a waiting period until all the tumors had implanted and grown to reach the approximate same volume of 250 mm^3^ (on day zero), when the injection of animals began (vertical arrows). Intra-tumor injections of INXS-plasmid or empty-plasmid were performed every third day over a period of 15 days. (B) Tumor volume was monitored by caliper on the days of injection in six different animals from each of two groups, which were injected either with INXS-plasmid (blue) or control empty-plasmid (black). The data are the mean ± SD of measurements from the six animals of each injection group. (C) An EGF-labeled dye marker was detected in the tumor by *in vivo* scanning with a near-infrared optical imaging system. Only one representative mouse is shown for each group, namely, INXS-plasmid or control empty-plasmid. (D) Pictures of the scanned animals, taken on day 15; note the difference in size between the tumors of the two animals, as indicated by arrows. (E) On day 15, all six animals from each of the two groups were euthanized, and their tumors were excised and photographed. Subsequently, tumors were formalin-fixed, paraffin-embedded, stained and observed by light microscopy. Arrows point to tumor peripheral vascularization. (F) Average weights of the excised tumors for each of the two injection groups, *INXS-*plasmid (blue) or control empty-plasmid (black). The data are the mean ± SD of measurements from the six animals of each injection group. An additional animal whose tumor was injected with only transfection solution is shown (vehicle, white bar). (G) *INXS* lncRNA (blue), *BCL-XL* mRNA (red) and *BCL-XS* mRNA (black) expression levels measured by RT-qPCR in the excised xenograft tumors. (H) *BCL-X* mRNA isoforms ratio in the excised xenograft tumors. \*(*P* \<0.05), \*\*(*P* \<0.01) and \*\*\*(*P* \<0.001).](gku561fig8){#F8}

In parallel, we monitored tumor size through near-infrared optical imaging. Animals were injected in the tail vein with a fluorescently labeled Epidermal Growth Factor (EGF) marker and scanned at the beginning (day 0), in the middle (day 9) and at the end of the injection period (day 15). Images of two representative animals are shown (Figure [8C](#F8){ref-type="fig"}). A considerable reduction in tumor volume was observed in the animals from the group that received the pCEP4-INXS vector (Figure [8C](#F8){ref-type="fig"}, lower panels), while tumor growth over time was evident in the control group inoculated with empty vector (Figure [8C](#F8){ref-type="fig"}, upper panels). On day 15, the tumor size difference could be clearly visualized (Figure [8D](#F8){ref-type="fig"}). All mice were euthanized on day 15; the tumors were removed and photographed (Figure [8E](#F8){ref-type="fig"}). The tumors were formalin-fixed, paraffin-embedded and observed by light microscopy with hematoxylin and eosin stain (Figure [8E](#F8){ref-type="fig"}). In the *INXS*-injected tumors the vascularization was considerably reduced as compared with controls (Figure [8E](#F8){ref-type="fig"}).

The excised tumors were weighed and a marked 13-fold reduction in the mean tumor weight was observed in the *INXS*-injected tumors that remained (27 mg) compared with the empty-plasmid-injected tumors from the controls (339 mg) (Figure [8F](#F8){ref-type="fig"}). An additional animal that had a tumor injected with only transfection solution (vehicle) had a final tumor weight of 351 mg (Figure [8F](#F8){ref-type="fig"}).

Total RNA was extracted from the excised paraffin-embedded tumor samples, and *INXS* lncRNA and *BCL-X* mRNA isoforms were measured. A significant 5-fold higher level of *INXS* lncRNA was detected in the remaining tumor cells from the *INXS*-plasmid-injected tumors compared with the tumor cells from the empty-plasmid-injected controls (Figure [8G](#F8){ref-type="fig"}). In these *INXS*-injected excised tumors the *BCL-XS* mRNA was increased and the *BCL-XL* mRNA was reduced as compared with controls (Figure [8G](#F8){ref-type="fig"}). It is worth noting that even though the measurements were carried out with cells that did not die along the 15 days of *INXS*-plasmid injections, the *BCL-XS*/*BCL-XL* ratio was significantly increased 4-fold in these surviving tumor cells (Figure [8H](#F8){ref-type="fig"}). Those cells that had died along the 15 days of *INXS*-plasmid injections, causing the dramatic reduction in tumor size, were the ones likely expressing high levels of *INXS*. Taken together, these results show that the *INXS* lncRNA can reduce tumor size *in vivo*, thus having a tumor suppressor activity.

DISCUSSION {#SEC4}
==========

We identified a novel endogenous lncRNA with an apoptotic role, acting post-transcriptionally *in trans* at the level of *BCL-X* pre-mRNA splicing. *INXS* lncRNA is transcribed from the same *locus* as *BCL-X*, and its expression levels were lower in all tested cancer cell lines, compared with immortalized non-tumor cell lines from the same tissues of origin and in kidney tumor tissue compared with adjacent non-tumor from clear cell renal cell carcinoma patient samples. This suggests that down-regulation of *INXS* lncRNA might be one of the factors conferring tumor resistance to apoptosis.

*INXS* is one of thousands of unspliced lncRNAs that are transcribed from intronic regions of 74% of the protein-coding genes ([@B49]), making them a part of the widespread non-coding transcription that is estimated to arise from at least 75% to 90% of the human genome ([@B50],[@B51]). *INXS*-mediated apoptosis, induced by *BCL-XS*, exemplifies a novel functional role exerted by a member of the class of unspliced intronic antisense lncRNAs; this class has been so far implicated in gene regulation at the transcriptional level through the recruitment of polycomb repressor complex 2 (PRC2) by intronic antisense *Kcnq1ot1* lncRNA to the *Kcnq1* locus to regulate 10 genes at this imprinted gene cluster ([@B52]), and the recruitment of PRC2 by intronic antisense *ANRASSF1* lncRNA to cause the location-specific *cis*-acting regulation of the tumor suppressor *RASSF1A* gene ([@B45]). Acting *in trans* at the post-transcriptional level, the unspliced intronic antisense lncRNA *Saf* was shown to have an anti-apoptotic oncogenic function by modifying the splicing of the *Fas* gene ([@B35]). It is conceivable that the characterization of additional members of the class of unspliced intronic antisense transcripts will lead to novel functional roles of lncRNAs acting at the post-transcriptional level.

Our results showed that increased levels of the unspliced antisense lncRNA *INXS* induces apoptosis by shifting *BCL-X* pre-mRNA splicing toward the pro-apoptotic *BCL-XS* isoform, leading to accumulation of BCL-XS protein. We also obtained evidence that *INXS* interacts with Sam68-containing splicing-modulator complexes. Thus, we propose the model mechanism shown in the scheme of Figure [9](#F9){ref-type="fig"}, in which we postulate that *INXS* endogenous expression is required to shift *BCL-X* pre-mRNA splicing toward *BCL-XS* pro-apoptotic isoform and can be induced by apoptotic agents. When *INXS* is absent or expressed at low levels, such as in cancer tissues, the predominant output of *BCL-X* pre-mRNA splicing is the anti-apoptotic *BCL-XL* isoform (Figure [9](#F9){ref-type="fig"}, pathway 1). In contrast, augmented levels of *INXS* (Figure [9](#F9){ref-type="fig"}, pathway 2) would interfere with the positioning and/or accessibility of splice factors to the alternative distal 5′ donor splice site on intron 2 of the pre-mRNA and favor the positioning of the splicing machinery to increase the abundance of the *BCL-XS* isoform, leading to an increase in BCL-XS protein and to cell apoptosis. Sam68 is not required for the accumulation of *BCL-XL* isoform as determined by Paronetto *et al.* ([@B12]), and a recent paper by Bielli *et al.* ([@B53]) shows that the transcription factor FBI-1 reduces Sam68 binding to *BCL-X* mRNA and that the absence of Sam68 favors the anti-apoptotic *BCL-XL* isoform.

![Proposed model of action of *INXS* lncRNA. *BCL-X* pre-mRNA undergoes either a *BCL-XL* anti-apoptotic or *BCL-XS* pro-apoptotic alternative processing ([@B4]). We propose that the control of *BCL-X* pre-mRNA alternative splicing, between pathway \[1\] toward *BCL-XL* anti-apoptotic isoform and pathway \[2\] toward *BCL-XS* pro-apoptotic isoform, depends on *INXS* endogenous lncRNA. Apoptosis inducing agents, such as UV-C light exposure, serum starvation or anti-cancer drugs, lead to an increased expression of endogenous *INXS*. Sam68 increases the level of the pro-apoptotic *BCL-XS* isoform, while its absence leads to the accumulation of *BCL-XL* ([@B12]). We propose that the augmented levels of *INXS* would favor the positioning of Sam68 splicing-modulator and of possible additional splice factors (SF) of the splicing machinery near the distal donor 5′ splice site on the pre-mRNA (5′ss, dotted blue line) and favor the splicing predominantly through pathway 2, thus leading to BCL-XS protein synthesis and to apoptosis.](gku561fig9){#F9}

*BCL-X* alternative splicing has emerged as a target for molecular therapy in cancer treatment ([@B4],[@B6],[@B8],[@B46]), following the early demonstration by Boise *et al.* ([@B4]) that *BCL-X* long and short isoforms exhibit opposing anti-apoptotic or pro-apoptotic functions, and act as dominant regulators of apoptotic cell death. The *in vivo* therapeutic potential of splice-switching oligonucleotides has been consistently explored in many diseases ([@B50],[@B54]), including the switching of *BCL-X* splicing in cancer ([@B46]); nevertheless, there are still hurdles that must be overcome, such as eventually achieving an improved cell-killing efficiency to overcome the present inability of these splice-switching oligonucleotides alone to cause apoptosis ([@B6],[@B8],[@B46]). The possibility seems to be open for a very effective gene-specific splice shifting toward pro-apoptotic *BCL-XS* that is accompanied by apoptosis, via a targeted induction of *INXS* lncRNA expression. We speculate that the *INXS* 1.9 kb transcript is effective in causing apoptosis because this endogenous lncRNA would have the potential to adopt a complex secondary/tertiary structure that could facilitate binding and possibly recruitment of splicing modulators, such as Sam68 protein, in a manner that might have been evolutionarily selected as part of a concerted mechanism. Overexpression or knockdown of *INXS* did not affect the splicing of two other genes that are known targets of Sam68, namely, *cyclin D1* ([@B47]) and *SF2/ASF* ([@B48]), suggesting that *INXS* does not exert a global role on Sam68-mediated alternative splicing, and that the specificity might arise from a portion of *INXS* eventually establishing a direct RNA/RNA base pair with the target *BCL-X* pre-mRNA. Further studies on modulating the endogenous expression of *INXS* and on determining the detailed molecular mechanism of action of *INXS* are warranted.

Most importantly, the effect of *INXS* lncRNA on the *BCL-X* splicing may eventually have less off-target effects than the anti-cancer drugs, which are known to induce the opposing anti-apoptotic splice variants of many other apoptotic genes, while causing a shift toward pro-apoptotic *BCL-XS* splicing ([@B55]). In this respect, it has been shown that most of the 20 tested anti-cancer drugs favor the anti-apoptotic splicing event on the *Fas* gene ([@B55]), while shifting *BCL-X* splicing by different degrees toward the pro-apoptotic isoform.

In a broader perspective, the identification of *INXS* as the first lncRNA that acts on splicing and induces apoptosis, calls the attention to the importance of looking at the functional roles and at the modes of induction of other lncRNAs possibly acting on splicing events that occur in apoptotic genes. Moreover, our INXS-plasmid injection experiments in a mouse xenograft model serve as a proof of concept that tumor regression could be effectively obtained *in vivo*. It is tempting to assume that controlling and/or conditionally increasing *INXS* expression in tumor cells could effectively induce apoptosis and limit tumorigenesis, and that the *INXS* lncRNA may represent a target to be explored in a molecular-based cancer therapy.

ACCESSION NUMBER {#SEC5}
================

*INXS* Accession number in GenBank: KC505631

SUPPLEMENTARY DATA {#SEC6}
==================

[Supplementary Data](http://nar.oxfordjournals.org/lookup/suppl/doi:10.1093/nar/gku561/-/DC1) are available at NAR Online.
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